Last reviewed · How we verify
HSS 3% — Competitive Intelligence Brief
phase 3
Osmotic agent / Hypertonic saline
Neurology / Critical Care
Small molecule
Live · refreshed every 30 min
Target snapshot
HSS 3% (HSS 3%) — Ministry of Health, Spain. HSS 3% is a hypertonic saline solution that draws fluid from tissues into the vascular space through osmotic gradient, reducing intracranial pressure and cerebral edema.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HSS 3% TARGET | HSS 3% | Ministry of Health, Spain | phase 3 | Osmotic agent / Hypertonic saline | ||
| NaCl 3% | NaCl 3% | Raphaelle Jaquet-Pilloud | phase 3 | Osmotic agent / Hypertonic saline |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Osmotic agent / Hypertonic saline class)
- Ministry of Health, Spain · 1 drug in this class
- Raphaelle Jaquet-Pilloud · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HSS 3% CI watch — RSS
- HSS 3% CI watch — Atom
- HSS 3% CI watch — JSON
- HSS 3% alone — RSS
- Whole Osmotic agent / Hypertonic saline class — RSS
Cite this brief
Drug Landscape (2026). HSS 3% — Competitive Intelligence Brief. https://druglandscape.com/ci/hss-3. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab